Insider Selling: 10x Genomics (NASDAQ:TXG) CEO Sells 13,261 Shares of Stock

by · The Cerbat Gem

10x Genomics (NASDAQ:TXG – Get Free Report) CEO Serge Saxonov sold 13,261 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $251,959.00. Following the completion of the transaction, the chief executive officer directly owned 1,021,556 shares in the company, valued at approximately $19,409,564. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

10x Genomics Stock Down 5.3%

Shares of TXG stock traded down $1.06 on Tuesday, reaching $19.07. The company’s stock had a trading volume of 5,111,169 shares, compared to its average volume of 3,246,832. The company has a market capitalization of $2.41 billion, a P/E ratio of -30.76 and a beta of 2.13. 10x Genomics has a 12-month low of $6.78 and a 12-month high of $20.34. The stock’s 50 day simple moving average is $13.55 and its 200-day simple moving average is $12.44.

10x Genomics (NASDAQ:TXG – Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.05. The business had revenue of $149.00 million during the quarter, compared to analysts’ expectations of $142.50 million. 10x Genomics had a negative return on equity of 11.50% and a negative net margin of 11.89%.The firm’s revenue was down 1.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.30) earnings per share. 10x Genomics has set its Q4 2025 guidance at EPS. Research analysts expect that 10x Genomics will post -1.43 EPS for the current year.

Analysts Set New Price Targets

TXG has been the topic of several research analyst reports. Canaccord Genuity Group upped their price objective on shares of 10x Genomics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a research note on Monday, November 17th. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on shares of 10x Genomics and gave the company a “hold” rating in a research report on Friday, August 8th. Piper Sandler lifted their price objective on shares of 10x Genomics from $15.00 to $19.00 and gave the stock a “neutral” rating in a report on Tuesday, November 11th. Finally, Morgan Stanley reduced their target price on 10x Genomics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $14.88.

Get Our Latest Analysis on TXG

Institutional Investors Weigh In On 10x Genomics

Hedge funds have recently made changes to their positions in the business. CIBC Bancorp USA Inc. purchased a new stake in shares of 10x Genomics in the 3rd quarter valued at $134,000. Jacobs Levy Equity Management Inc. raised its position in 10x Genomics by 22.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,947,989 shares of the company’s stock worth $34,462,000 after purchasing an additional 550,250 shares during the period. CANADA LIFE ASSURANCE Co boosted its position in 10x Genomics by 14.9% during the third quarter. CANADA LIFE ASSURANCE Co now owns 25,365 shares of the company’s stock valued at $287,000 after buying an additional 3,296 shares during the period. XTX Topco Ltd grew its stake in shares of 10x Genomics by 41.0% during the third quarter. XTX Topco Ltd now owns 81,070 shares of the company’s stock valued at $948,000 after buying an additional 23,555 shares during the last quarter. Finally, Voleon Capital Management LP grew its stake in shares of 10x Genomics by 73.9% during the third quarter. Voleon Capital Management LP now owns 306,101 shares of the company’s stock valued at $3,578,000 after buying an additional 130,094 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Company Profile

(Get Free Report)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Recommended Stories